SCHEMBL6180856

SCHEMBL6180856

O=C(NC1CCN(Cc2ccccc2)C1)C(O)(c1ccccc1)C1CCCC1

nearest known ligand 0.87

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 16/20 0.87
CHRM1 P11229 16/20 0.87
CHRM3 P20309 16/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126550 1.00 CHRM2 (0.87) CHRM2CHRM1CHRM3
SCHEMBL4879759 0.85 CHRM3 (0.67) CHRM2CHRM1CHRM3
SCHEMBL4084970 0.84 CHRM2 (0.72) CHRM2CHRM1CHRM3
SCHEMBL4084084 0.84 CHRM2 (0.72) CHRM2CHRM1CHRM3
SCHEMBL5948020 0.83 CHRM2 (0.71) CHRM2CHRM1CHRM3
SCHEMBL5948227 0.83 CHRM2 (0.71) CHRM2CHRM1CHRM3
SCHEMBL6585812 0.82 CHRM2 (1.00) CHRM2CHRM1CHRM3
SCHEMBL5948401 0.82 CHRM2 (0.69) CHRM2CHRM1CHRM3
SCHEMBL5948399 0.82 CHRM2 (0.69) CHRM2CHRM1CHRM3
SCHEMBL6589582 0.81 CHRM2 (1.00) CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583741-A1 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories, Limited (IN) 2005-10-12 EP claimed
WO-2004056767-A1 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2004-07-08 WO claimed
EP-1583741-A1 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories, Limited (IN) 2005-10-12 EP disclosed
WO-2004056767-A1 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2004-07-08 WO disclosed